

late-onset Parkinson's disease: a genome-wide

linkage and sequencing study. 2015, *Lancet Neurol*, in press.

28) Fujita H, Yagishita N, Aratani S, Saito - Fujita T, Morota S, Yamano Y, Hansson M, Inazu M, Kokuba H, Sudo K, Sato E, Kawahara K, Nakajima F, Hasegawa D, Higuchi I, Sato T, Araya N, Usui C, Nishioka K, Nakatani Y, Maruyama I, Usui M, Hara N, Uchino H, Elmer E, Nishioka K, Nakajima T. The E3 ligase synoviolin controls body weight and mitochondrial biogenesis through negative regulation of PGC - 1 β . 2015, *EMBO J*, in press.

29) Matsuo H, Tomiyama H, Satake W, Chiba T, Onoue H, Kawamura Y, Nakayama A, Shimizu S, Sakiyama M, Funayama M, Nishioka K, Shimizu T, Kaida K, Kamakura K, Toda T, Hattori N, Shinomiya N. ABCG2 variant has opposing effects on onset ages of Parkinson's disease and gout. *Ann Clin Tranl Neurol*. 2015 in press.

30) Nishioka K, Tanaka R, Shimura H, Hirano K, Hatano T, Miyakawa K, Arai H, Hattori N, Urabe T. Quantitative evaluation of electroconvulsive therapy for Parkinson's disease with refractory psychiatric symptoms. *J Neural Transm*. 2014 Nov;121(11):1405-10.

31) Nishioka K, Funayama M, Vilariño-Güell C, Ogaki K, Li Y, Sasaki R, Kokubo Y, Kuzuhara S, Kachergus JM, Cobb SA, Tahakashi H, Mizuno Y, Farrer MJ, Ross OA, Hattori N. EIF4G1 gene mutations are not a common cause of Parkinson's disease in the Japanese population. *Parkinsonism Relat Disord*. 2014;20:659-61.

32) Nishioka K, Tanaka R, Tsutsumi S, Yamashiro K, Nakahara M, Shimura H, Hattori N, Urabe T. Cerebral dural sinus thrombosis associated with adenomyosis: a case report. *J Stroke Cerebrovasc Dis*. 2014; 23:1985-7.

33) Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, Nakamura H; DELIRIA-J Group.

Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial.

JAMA Psychiatry. 2014;71(4):397-403

34) Hatta K, Otachi T, Fujita K, Morikawa F, Ito S, Tomiyama H, Abe T, Sudo Y, Takebayashi H, Yamashita T, Katayama S, Nakase R, Shirai Y, Usui C, Nakamura H, Ito H, Hirata T, Sawa Y; JAST study group. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia. *Schizophr Res*. 2014;158(1-3):213-22

35) Fujita H, Yagishita N, Aratani S, Saito-Fujita T, Morota S, Yamano Y, Magnus J.H, Inazu M, Kokuba H, Sudo K, Sato E, Kawahara K, Nakajima F, Hasegawa D, Higuchi I, Sato T, Araya N, Usui C, Nishioka K, Nakatani Y, Maruyama I, Usui M, Hara N, Uchino

H, Eskil E, Nishioka K, Nakajima T The E3 ligase synoviolin controls body weight and mitochondrial biogenesis through negative regulation of PGC-1 β EMBO J 10.15252/embj.201489897 (2015)

36) 渡邊高志、長田賢一、芳賀俊明、武藤亜矢、小川百合子、田口 篤、浅利翔平、中野三穂、貴家 康男、山口 登：アリピプラゾールの長期投与によるジゴキシンの血中/脳内濃度の変化、聖マリアンナ医科大学誌, 2015, in press

本報告書は、厚生労働省の慢性の痛み解明研究委託事業による委託業務として、東京医科大学が実施した平成27年度「線維筋痛症の病因・病態の解明と客観的診断・評価法の開発及びトータルマネジメントの確立に関する戦略的総合研究」の成果を取りまとめたものです。